Based on these latter data and the establishment of INRG classification system, MYCN amplification was upgraded to high risk [14] and chemotherapy in early stage MYCN amplified neuroblastoma patients is now being considered in a Phase III study, conducted by SIOPEN, which evaluates the benefit of 6 cycles of chemotherapy (carboplatin, etoposide, vincristine, cyclophosphamide, and doxorubicin) combined with local radiotherapy followed by 6 cycles of cis-retinoic acid. Here, MYCN is linked to neuroblastoma.